跳至主要内容
临床试验/NCT02827565
NCT02827565已完成不适用

Prospective Study of Technical Optimization of the Detection of KRAS Mutations, BRAF and NRAS by Next Generation Sequencing on Tumor DNA Circulating in Metastatic Colorectal Cancer.

Institut de Cancérologie de Lorraine1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年2月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Technical Optimization of KRAS, BRAF and NRAS mutations detection

研究概览

简要总结

The objective of this study is to optimize the search by next-generation sequencing (NGS) mutations in the KRAS, BRAF and NRAS on circulating tumor DNA and compare the genetic profiles obtained with those from tumors embedded in paraffin

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients with metastatic or locally advanced colorectal carcinoma with a KRAS, BRAF or NRAS mutation
  • •Age ≥ 18 years
  • •Patient information and written informed consent form signed
  • •Patient must be affiliated to a social security system

排除标准

  • •Patients whose health-cons indicates a blood sample 10mL
  • •Age < 18 years
  • •Pregnant or breast feeding females
  • •Persons deprived of liberty or under supervision

研究组 & 干预措施

CircuLOR-1

Experimental

KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations

干预措施: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA (Other)

结局指标

主要结局

Technical Optimization of KRAS, BRAF and NRAS mutations detection

时间窗: 1 day

Optimize the detection of mutations of KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAf (exon 15) genes, using the next-generation sequencing technology from circulating tumor DNA in patients with metastatic colorectal cancer.

次要结局

  • KRAS, NRAS et BRAF mutational status(1 day)

研究者

发起方
Institut de Cancérologie de Lorraine
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Technical Optimization of Detection of KRAS, BRAF... | 临床试验